Background:

ALK inhibitors are potential anti-cancer drugs that act on tumours with variations of anaplastic lymphoma kinase (ALK) such as an EML4-ALK [1]. As the same as ALK inhibitor 1, ALK inhibitor 2 is a novel and selective inhibitor for the ALK kinase as well.
In vitro: ALK inhibitor 2 (2-[[5-chloro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino] pyrimidin-4-yl]amino]-N-methylbenzenesulfonamide) is a chemical analogue of LDK378 that is a potent ALK inhibitor [2].
In vivo: No animal in-vivo data available currently.
Clinical trial: Currently ALK inhibitor 2 is only in the preclinical developlent stage and no clinical data are available.
Reference:
[1] Palmer RH, Vernersson E, Grabbe C, Hallberg B. Anaplastic lymphoma kinase: signalling in development and disease. Biochem J. 2009;420(3):345-61.
[2] Marsilje TH, Pei W, Chen B, Lu W, et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem. 2013;56(14):5675-90.